New blood test detects non-alcoholic steatohepatitis

July 06, 2006

A case-control study has found that a simple test can indicate the presence of non-alcoholic steatosis by measuring caspase 3-generated cytokeratin-18 fragments in the blood. The test could eliminate the need for invasive liver biopsies, currently the only reliable way to diagnose the disease.

The results of the study are published in the July 2006 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD). Published by John Wiley & Sons, Inc., Hepatology is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/hepatology.

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in both children and adults. While simple steatosis - an accumulation of fat in the liver - is the usual form and is benign, nonalcoholic steatohepatitis (NASH) can be a very serious condition. As many as 25 percent of patients progress to cirrhosis and can have complications like liver failure and hepatocellular carcinoma. But until now, only an invasive liver biopsy, which carries a risk of complications, could distinguish between the two.

Led by Anna Wieckowska, M.D. of the Department of Gastroenterology and Hepatology at the Cleveland Clinic Foundation, researchers considered a non-invasive way to diagnose NASH and assess histologic severity using a simple blood test. They looked for indicators of liver cell death, specifically, caspase-generated CK-18 fragments which have been shown to label early apoptotic cells.

They tested the blood of 39 patients undergoing liver biopsy for suspected NAFLD and compared the results to the biopsies, and also to the blood of 35 healthy age-matched controls.

The plasma levels of CK-18 fragments ranged from 105.5 to 2306.4 U/L and were significantly higher in patients undergoing liver biopsy compared to the healthy controls. The levels were strikingly higher in patients whose liver biopsies resulted in a definite diagnosis of NASH, compared with patients whose liver biopsies showed no NASH, or were normal.

Additionally, caspase activity levels independently predicted the presence of NASH. The risk of definitive NASH on liver biopsy increased with increasing plasma levels of caspase 3-generated CK-18 fragments. For every 50 U/L increase in CK-18 levels, the likelihood of having "definitive NASH" increased 86 percent.

"In summary, our findings suggest that non-invasive monitoring of hepatocyte apoptosis in blood of patients with NAFLD is a reliable tool to differentiate NASH from 'not NASH' in patients with suspected NAFLD," the authors report.

The test showed high sensitivity, specificity, and positive and negative predictive value, leading the authors to suggest it as an important potential clinical tool. "Future large studies are needed to confirm these observations," they conclude. And they are currently planning a large multi-center prospective validation study.
-end-
Article: "In Vivo Assessment of Liver Cell Apoptosis as a Novel Biomarker of Disease Severity in Nonalcoholic Fatty Liver Disease," Anna Wieckowska, Nizar N. Zein, Lisa M. Yerian, A. Rocio Lopez, Arthur J. McCullough, Ariel E. Feldstein, Hepatology; July 2006 (DOI: 10.1002/hep.21223).

Wiley

Related Biopsies Articles from Brightsurf:

Imaging technique could replace tissue biopsies in assessing drug resistance in cancer
Imaging techniques could replace the need for invasive tissue biopsies in helping rapidly determine whether cancer treatments are working effectively, according to researchers at the University of Cambridge.

Fresh tumor biopsies in world-first technique for cancer treatments
An innovative technique to improve cancer treatments using tumour biopsies less than 30 minutes after they're taken has been developed at The University of Queensland.

Urine test could reduce unnecessary prostate cancer biopsies
Unnecessary prostate cancer biopsies could be reduced by 60% thanks to new research from the University of East Anglia.

Secrets of lung cancer spread found in patients' blood and biopsies
Early signs that a patient's lung cancer may spread and become untreatable can be picked up in samples of their blood and tumor, according to a trio of papers published in Nature Medicine.

NUS invention makes biopsies less invasive and more informative
A team of researchers from the National University of Singapore (NUS) has developed a novel technology that could sensitively and accurately detect and classify cancer cells, as well as determine the disease aggressiveness from the least invasive biopsies.

New blood test for prostate cancer is highly-accurate and avoids invasive biopsies
A new and simple blood test has been found to efficiently and accurately detect the presence of aggressive prostate cancer, according to research by Queen Mary University of London.

Liquid biopsies reveal genetic alterations linked to cancer drug resistance
New research shows that liquid biopsies taken from blood provide a more complete picture than traditional biopsy of both the genetic diversity of a patient's cancer and how tumors evolve drug resistance at the molecular level.

Inexpensive equipment and training can improve melanoma detection and reduce biopsies
Researchers say non-dermatologist physicians can make earlier and more accurate diagnoses of melanomas using a dermatoscope.

Bolstering biopsies: Testing individual cells to guide treatment
In research that could make biopsies more useful for many diseases, scientists have used a powerful new tool to zero in on individual cells in a patient's diseased organ and reveal the cells' underlying glitches in gene expression -- information that may allow for more precise and effective treatment.

Making the invisible visible: New method opens unexplored realms for liquid biopsies
A new approach to RNA sequencing reveals thousands of previously inaccessible RNA fragments in blood plasma that might serve as disease- and organ-specific biomarkers

Read More: Biopsies News and Biopsies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.